Opko Health Inc(OPK) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 4:14 AM ET (Korea 9/15 17:14)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.1 | Insider Own | 51.22% | Shs Outstand | 746.0M | Perf Week | -4.88% |
| Market Cap | 1.16B | Forward P/E | - | EPS next Y | -21.64% | Insider Trans | - | Shs Float | 364.0M | Perf Month | 11.43% |
| Enterprise Value | 1.26B | PEG | - | EPS next Q | -0.07 | Inst Own | 28.88% | Short Float | 9.49% | Perf Quarter | 9.86% |
| Income | -0.07B | P/S | 1.98 | EPS this Y | 25.56% | Inst Trans | 0.55% | Short Ratio | 9.61 | Perf Half Y | 31.09% |
| Sales | 0.59B | P/B | 0.98 | EPS next 5Y | 6.53% | ROA | -3.83% | Short Interest | 34.56M | Perf YTD | 23.81% |
| Book/sh | 1.59 | P/C | 3.87 | EPS past 3/5Y | 13.03% - | ROE | -5.88% | 52W High | -9.83% ($1.73) | Perf Year | 11.43% |
| Cash/sh | 0.4 | P/FCF | - | Sales past 3/5Y | -15.45% -15.82% | ROIC | -4.67% | 52W Low | 59.69% ($0.98) | Perf 3Y | -5.45% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 58.54% | Gross Margin | 27.75% | Volatility(W/M) | 4.9% 4.8% | Perf 5Y | -55.17% |
| Dividend TTM | - | EV/Sales | 2.15 | Sales Y/Y TTM | -11.46% | Oper. Margin | -28.56% | ATR (14) | 0.08 | Perf 10Y | -84.69% |
| Dividend Ex-Date | - | Quick Ratio | 2.93 | EPS Q/Q | 94.11% | Profit Margin | -12.4% | RSI (14) | 56.07 | Recom | 1.67 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.35 | Sales Q/Q | 4.32% | SMA20 | 3.11% ($1.51) | Beta | 1.51 | Target Price | $4.38 |
| Payout | - | Debt/Eq | 0.34 | Earnings | 2026/7/27 | SMA50 | 11.54% ($1.4) | Rel Volume | 0.6 | Prev Close | $1.57 |
| Employees | 2275 | LT Debt/Eq | 0.32 | EPS/Sales Surpr. | 87.5% 24.59% | SMA200 | 19.83% ($1.3) | Avg Volume(3M) | 3.60M | Price | $1.56 |
| IPO | 1995/11/2 | Option/Short | Yes/Yes | Trades | 7140 | Volume | 2,147,327 | Change | -0.64% |
Company
OPK is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 OPKO Health (OPK) is a diversified U.S. healthcare company that operates both diagnostics and pharmaceuticals. Its diagnostics segment, through its subsidiary BioReference Health, offers urology- and oncology-focused tests (4Kscore, GenPath), while its pharmaceutical segment is anchored by Rayaldee, a treatment for chronic kidney disease, and NGENLA (somatrogon), a pediatric growth hormone. The company is distinguished by its business model that combines diagnostics with novel drug development.
Over the past 1 year, on the higher side
10% below its 1-year high.
OPK has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +25.6% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -5.5% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 28.9%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
TINY 0.01%
QQQS 0.00%
ISRA 0.00%
XHS 0.00%
IHF 0.00%It ranks #4 in the industry
Based on market cap of $1B.
OPK $1B PER -
TMO $227B PER 33.0
DHR $143B PER 36.1
NTRA $49B PER -
FAQ
What kind of company is OPK?
OPK belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of OPK?
The market cap of OPK is approximately $1.2B, ranking 2,526 within its sector.
What is the 52-week high and low for OPK?
OPK has recorded a 52-week high of $1.73 and a low of $0.98.
